Explore the words cloud of the STOPFOP project. It provides you a very rough idea of what is the project "STOPFOP" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||1˙999˙712 €|
|EC max contribution||999˙710 € (50%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-05-01 to 2022-04-30|
Take a look of project's partnership.
|1||STICHTING VUMC||NL (AMSTERDAM)||coordinator||525˙756.00|
|2||THE ROYAL NATIONAL ORTHOPAEDIC HOSPITAL NATIONAL HEALTH SERVICE TRUST||UK (STANMORE)||participant||253˙559.00|
|3||KLINIKUM GARMISCH-PARTENKIRCHEN GMBH||DE (GARMISCH PARTENKIRCHEN)||participant||216˙645.00|
|4||THE BRIGHAM AND WOMEN'S HOSPITAL INC||US (BOSTON MA)||participant||1˙875.00|
|5||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||1˙875.00|
|6||ASTRAZENECA AB||SE (SODERTAELJE)||participant||0.00|
Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling and life-shortening congenital syndrome for which no effective therapies exist. Repurposing of AZD0530 (saracatinib, AstraZeneca) would be an ideal solution for de-risking early clinical studies. Using existing assets and investments, this may allow more affordable pricing once an indication is approved. Ectopic bone is formed in soft tissues due to activating mutations in the bone morphogenetic protein receptor kinase ALK2/ACVR1, leading to progressive contractures and early death. Preclinical studies showed AZD0530, previously unexplored in FOP, to be a potent (5nM) inhibitor of ALK2 kinase and ALK2-R206H-mediated neofunction after activin stimulation. In mice, AZD0530 blocked ectopic bone formation preserving limb movement.
Hypothesis: AZD0530 will reduce ectopic bone formation and progressive disability in people with FOP.
AIM: to provide proof of concept that AZD0530 is an effective drug in the treatment of patients with FOP.
Methods: Based on the rarity of the disease and expected drug efficacy (50% reduction in new bone), a phase 2A proof of concept study including a 6 month randomized placebo controlled study and 12 month open label extension study using historical data, is proposed including 16 adults with active FOP disease. The study will be performed in three European FOP expert Centers (Amsterdam The Netherlands – Lead, London UK, and Garmen Partenkirchen Germany). The study will be performed in collaboration with the expert preclinical teams at the Universities of Oxford and Harvard. FOP expert and patient engagement as well as safety will be ensured by establishing advisory, DSM and stakeholder boards. Early involvement of the regulatory agencies are planned.
Expectations: we will develop a roadmap for further studies and regulation of this new treatment option in FOP based on the results.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOPFOP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "STOPFOP" are provided by the European Opendata Portal: CORDIS opendata.
Antibiotic Distribution and Recovery in TissueRead More
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More